SCLEROSTIN: Pathogenesis of mastocytosis bone disease
Study summary
Mastocytosis is very rare and highly heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs and tissues.
Bones are the most frequent localization of systemic mastocytosis. The aim of our research was to explain the potential role of sclerostin in the pathogenesis of bone disease in mastocytosis.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Age \> 18 years
* Mastocytosis defined according to WHO criteria
* Known KIT mutation status
Exclusion Criteria:
* History of organ transplant
* Inability to give informed consent
* Pregnancy, Breastfeeding
* Vulnerable Patient, defined as: patient with another uncontrolled severe disease; patient under juridical protection
Primary outcome measure(s)
plasma sclerostin measurements (in pmol/l) SOST gene expression by Real-Time PCR dimensions of osteolytic lesions on low-dose computed tomography (in mm) dimensions of osteosclerotic lesions on low-dose computed tomography (in mm) — 1 year The Primary Outcome Measures concern:
* the measurements of plasma levels of sclerostin and its bioactive form in patients with mastocytosis and healthy volunteers
* the measurements of levels of sclerostin and its bioactive form in HMC-1.2 human mast cells unstimulated and stimutaled with Il-6
dimensions of osteolytic lesions (in mm) — 1 year The Primary Outcome Measures concern:
\- the measurements of the dimensions of osteolytic bone lesions on low-dose computed tomography in patients with mastocytosis
dimensions of osteosclerotic lesions (in mm) — 1 year The Primary Outcome Measures concern:
\- the measurements of the dimensions of osteosclerotic bone lesions on low-dose computed tomography in patients with mastocytosis
Trial sites (1)
Facility
City
Region
Status
Department of Hematooncology and Bone Marrow Transplantation
Lublin
Lublin Voivodeship
Recruiting
More Medical University of Lublin trials in Poland
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.